Dive in
We have our own point of view on the people, technologies, and conversations that will shape the future.
The Anthology Fund is a $100 million initiative created through a partnership between Menlo Ventures and Anthropic to fuel the next generation of AI startups.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
With supply chain companies increasingly recognizing the advantages of shared data and optimized workflows, a new era of collaboration is on the horizon.
Observe’s success in moving to the enterprise provides a playbook for both startups and enterprises on how to leverage GenAI to win together.
The first AI-native enterprise apps broke from the pack, distinguishing themselves from the wave of AI apps that emerged last year following the rise of OpenAI and Anthropic.
AI-generated video is on the verge of its ChatGPT moment.
We’re excited to partner closely with the team at Unstructured and are confident that they have firmly established themselves as the ETL leader for AI/ML workloads of the future.
For those in healthcare, JPM provides the unofficial kickoff to every new year with a chance to recap the year before and inform our view on the year ahead.
Generative AI is a powerful technology in the hands of both good and bad actors. While cybercriminals can use GenAI to complicate and expand existing threats, it’s also an incredible defensive technology.
In the race to adopt generative AI, every enterprise grapples with a common concern: security.
The future of the modern AI stack is being decided now. More than ever, machines are capable of reasoning, creation, and creativity, and these new capabilities are driving enterprises to reconstruct their tech stacks.
In November 2023, we hosted an exclusive gathering of leading investors, entrepreneurs, and industry luminaries at Menlo Ventures’ Annual Meeting + CEO Summit.
Menlo Ventures surveyed more than 450 enterprise executives to provide a view into generative AI adoption in the enterprise today.
With Cleanlab, AI teams automate weeks of manual data labeling and bypass dozens of engineering hours for model training and deployment.
Drug design is both a natural fit and a unique challenge for generative AI, given large but messy datasets, time and cost of real-world testing, and the complexity of human trials.
While navigating this exciting yet complex landscape may seem daunting for startups, lessons from past tech waves, along with a thoughtful, strategic approach, can help illuminate the path forward.
